Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)
about
Contralateral Prophylactic Mastectomy (CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks.Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled TrialsDoes neoadjuvant chemotherapy affect morbidity, mortality, reoperations, or readmissions in patients undergoing lumpectomy or mastectomy for breast cancer?Surgical Outcomes for Mastectomy Patients Receiving Neoadjuvant Chemotherapy: A Propensity-Matched Analysis.Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).Quality of life after mastectomy with or without immediate breast reconstruction.Biology and Management of Patients With Triple-Negative Breast Cancer.Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review.Trends and controversies in multidisciplinary care of the patient with breast cancer.Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States.Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).Nomogram predicts survival benefit from preoperative radiotherapy for non-metastatic breast cancer: A SEER-based study.The Shifting Paradigm for Breast Cancer Surgery in Patients Undergoing Neoadjuvant Chemotherapy.Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02).Neoadjuvant chemotherapy among patients treated for nonmetastatic breast cancer in a population with a high HIV prevalence in Johannesburg, South Africa.The Impact of Neoadjuvant Treatment on Surgical Options and Outcomes.Is there an Ideal Breast Conservation Rate for the Treatment of Breast Cancer?Magnetic resonance imaging patterns of tumor regression in breast cancer patients after neo-adjuvant chemotherapy, and an analysis of the influencing factors.Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy
P2860
Q31118195-705629C8-93BC-42DD-85E1-75D9063CD7D4Q35881780-7700649D-9F9F-4E2E-8F9D-8165C8460654Q37626892-4527A97C-261C-443B-AAAC-A079063A816AQ37634012-5389F9D5-D891-4CBE-A436-6112BE30C8BEQ38704901-304CF77F-5D6C-43B1-B6C7-2F0295485159Q38841115-5AF1841C-8E0F-46F1-BADC-F3AB674ACDF1Q38893074-F72B64D5-EB60-4725-9E14-3E97E1355A7FQ39019484-6D9E966F-CAC0-47DB-90A7-3062F5F811F5Q39029485-0C2FBD6B-8CEE-4DC4-9B8F-37F38BA8663DQ39119467-336FE6E6-5DB2-4BD2-9392-5021727D8C36Q39242605-4F86CA1B-8AA4-4EE6-97F8-0294C6BDBF85Q39322051-55B6920B-F83B-4AED-946F-413E6BD135BDQ39568666-8375D3A3-1541-48F5-B5BE-E5C06F2C8927Q40168846-F503698D-ADCC-42C9-95BC-13CC3FA13B37Q50061760-2CD079AC-C890-453F-A5D2-A5A7272417E7Q50127275-3358A871-A2E0-409F-842D-FDD7B0C7E13DQ50422403-DC1A6A88-E462-490E-8DA2-F46F37F9013CQ53075430-0E9EF18F-69BD-4DB1-AE6B-48CC707F9A46Q53101382-BFE0DC3D-2735-4A96-8793-449CB4443945Q53364770-D8E03C97-B255-4259-8515-9576261239E0Q55438036-E2D56218-7434-4EBE-8109-B3F30BD7297FQ58806315-94EAF636-3B41-44D1-921E-12CB9F7766E4
P2860
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Impact of neoadjuvant chemothe ...... ts from CALGB 40603 (Alliance)
@ast
Impact of neoadjuvant chemothe ...... ts from CALGB 40603 (Alliance)
@en
type
label
Impact of neoadjuvant chemothe ...... ts from CALGB 40603 (Alliance)
@ast
Impact of neoadjuvant chemothe ...... ts from CALGB 40603 (Alliance)
@en
prefLabel
Impact of neoadjuvant chemothe ...... ts from CALGB 40603 (Alliance)
@ast
Impact of neoadjuvant chemothe ...... ts from CALGB 40603 (Alliance)
@en
P2093
P2860
P1433
P1476
Impact of neoadjuvant chemothe ...... ts from CALGB 40603 (Alliance)
@en
P2093
Alliance for Clinical Trials in Oncology
Clifford Hudis
Constance T Cirrincione
David W Ollila
Donald A Berry
Eric Winer
George Somlo
Mehra Golshan
Sara Jasinski
Tracey F Weisberg
P2860
P304
434-9; discussion 438-9
P356
10.1097/SLA.0000000000001417
P407
P577
2015-07-28T00:00:00Z